1. Successful Strategy for Prevention of Cytomegalovirus Interstitial Pneumonia After Human Leukocyte Antigen-Identical Bone Marrow Transplantation
- Author
-
Gerald J. Elfenbein, John Graham-Pole, Tariq Siddiqui, Samuel Gross, Robert B. Marcus, Terri Wikle-Fisher, Nancy P. Mendenhall, Kenneth H. Rand, Theresa M. Goedert, and Roy S. Weiner
- Subjects
Adult ,Microbiology (medical) ,Adolescent ,Pulmonary Fibrosis ,Attack rate ,Congenital cytomegalovirus infection ,Graft vs Host Disease ,Human leukocyte antigen ,Antigen ,HLA Antigens ,Risk Factors ,Pulmonary fibrosis ,Humans ,Transplantation, Homologous ,Medicine ,Interstitial pneumonia ,Child ,Bone Marrow Transplantation ,Biological Products ,biology ,business.industry ,Immunization, Passive ,Infant ,virus diseases ,medicine.disease ,Infectious Diseases ,Child, Preschool ,Cytomegalovirus Infections ,Immunology ,biology.protein ,Antibody ,business ,Complication - Abstract
Cytomegalovirus (CMV) interstitial pneumonia is a frequent and often fatal complication of allogeneic bone marrow transplantation. Because therapy for CMV pneumonia was, until recently, largely ineffective, prophylactic methods were explored. This study shows that the strategy of using CMV seronegative blood products for seronegative patients with seronegative donors or weekly administration of intravenous immunoglobulin for all other patients reduced the attack rate of CMV pneumonia. The results of this study are put into the perspective of previously published data.
- Published
- 1990